scholarly article | Q13442814 |
P50 | author | Luiz Zerbini | Q72622624 |
P2093 | author name string | Ricardo G Correa | |
Eduardo P Amaral | |||
Carina C Jank | |||
Eduardo L Nolasco | |||
Henrique B da Silva | |||
Nathalia C de Victo | |||
Rodrigo Atique | |||
Valesca Anschau | |||
P2860 | cites work | Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its activation | Q21142629 |
The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention | Q21245733 | ||
Wnt signaling pathways in urological cancers: past decades and still growing | Q21245761 | ||
VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling | Q22009049 | ||
The pro-apoptotic kinase Mst1 and its caspase cleavage products are direct inhibitors of Akt1 | Q24297392 | ||
MST1 is a multifunctional caspase-independent inhibitor of androgenic signaling | Q24300132 | ||
Wnt-11 promotes neuroendocrine-like differentiation, survival and migration of prostate cancer cells | Q24302096 | ||
Selective interaction of JNK protein kinase isoforms with transcription factors | Q24317346 | ||
Phosphoinositide 3-kinase/Akt inhibits MST1-mediated pro-apoptotic signaling through phosphorylation of threonine 120 | Q24321602 | ||
Synergistic activation of stress-activated protein kinase 1/c-Jun N-terminal kinase (SAPK1/JNK) isoforms by mitogen-activated protein kinase kinase 4 (MKK4) and MKK7 | Q24532197 | ||
FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells. | Q39666997 | ||
Common botanical compounds inhibit the hedgehog signaling pathway in prostate cancer | Q39714349 | ||
AMP-activated protein kinase (AMPK) cross-talks with canonical Wnt signaling via phosphorylation of beta-catenin at Ser 552. | Q39719643 | ||
Inhibiting TNF-mediated signaling: a novel therapeutic paradigm for androgen independent prostate cancer | Q39784222 | ||
Critical role of Smad2 in tumor suppression and transforming growth factor-beta-induced apoptosis of prostate epithelial cells | Q39874700 | ||
Natural derivatives of curcumin attenuate the Wnt/beta-catenin pathway through down-regulation of the transcriptional coactivator p300. | Q39918946 | ||
The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network | Q39948774 | ||
Induction of the SUMO-specific protease 1 transcription by the androgen receptor in prostate cancer cells | Q40068850 | ||
GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms | Q40179207 | ||
Regulation of androgen receptor activity by tyrosine phosphorylation. | Q40219614 | ||
Genomic Analysis Highlights the Role of the JAK-STAT Signaling in the Anti-proliferative Effects of Dietary Flavonoid-'Ashwagandha' in Prostate Cancer Cells | Q40310152 | ||
Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. | Q40350197 | ||
Prostate cancer cells promote osteoblastic bone metastases through Wnts | Q40377933 | ||
MAPK/ERK signaling in activated T cells inhibits CD95/Fas-mediated apoptosis downstream of DISC assembly | Q40430386 | ||
C/EBPdelta is a downstream mediator of IL-6 induced growth inhibition of prostate cancer cells | Q40503739 | ||
E17K substitution in AKT1 in prostate cancer | Q40528326 | ||
Distinct roles for the catalytic and hemopexin domains of membrane type 1-matrix metalloproteinase in substrate degradation and cell migration | Q40598211 | ||
An AU-rich element in the 3′ untranslated region of the C/EBPδ mRNA is important for protein binding during G0 growth arrest | Q40652748 | ||
Attenuation of Ras signaling restores androgen sensitivity to hormone-refractory C4-2 prostate cancer cells | Q40654217 | ||
Mitogen-activated protein kinase kinase 4 (MKK4) acts as a metastasis suppressor gene in human ovarian carcinoma. | Q40689238 | ||
Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3beta inhibition and nuclear beta-catenin accumulation | Q40725486 | ||
Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway . | Q40905632 | ||
FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease | Q40951616 | ||
Interleukin-6: a candidate mediator of human prostate cancer morbidity | Q41362792 | ||
Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor | Q41435735 | ||
Tgf-β1 produced by activated CD4(+) T Cells Antagonizes T Cell Surveillance of Tumor Development | Q42204363 | ||
The MAPK/ERK cascade targets both Elk-1 and cAMP response element-binding protein to control long-term potentiation-dependent gene expression in the dentate gyrus in vivo. | Q42488934 | ||
Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue | Q42490034 | ||
MYC and Prostate Cancer | Q42731671 | ||
Alterations in beta-catenin expression and localization in prostate cancer | Q42813475 | ||
Activation of p38 Mitogen-Activated Protein Kinase and c-Jun-NH2-Terminal Kinase by BMP-2 and Their Implication in the Stimulation of Osteoblastic Cell Differentiation | Q42834274 | ||
Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway | Q42855019 | ||
A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer | Q43202742 | ||
Promoter methylation in APC, RUNX3, and GSTP1 and mortality in prostate cancer patients | Q43430033 | ||
Co-operative functions between nuclear factors NFkappaB and CCAT/enhancer-binding protein-beta (C/EBP-beta) regulate the IL-6 promoter in autocrine human prostate cancer cells | Q45076496 | ||
KN-93 inhibits androgen receptor activity and induces cell death irrespective of p53 and Akt status in prostate cancer | Q45225061 | ||
Activin A enhances prostate cancer cell migration through activation of androgen receptor and is overexpressed in metastatic prostate cancer | Q46102160 | ||
Obesity and prostate cancer aggressiveness among African and Caucasian Americans in a population-based study | Q46895323 | ||
Gene expression analysis in prostate cancer: the importance of the endogenous control. | Q47215788 | ||
Antitumor effects of the novel quinazolinone MJ-33: inhibition of metastasis through the MAPK, AKT, NF-κB and AP-1 signaling pathways in DU145 human prostate cancer cells | Q47350125 | ||
Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study | Q47364687 | ||
Bone morphogenetic protein-10 suppresses the growth and aggressiveness of prostate cancer cells through a Smad independent pathway | Q47988622 | ||
On the rumors about the silent spring. Review of the scientific evidence linking occupational and environmental pesticide exposure to endocrine disruption health effects | Q34582049 | ||
Stat proteins and oncogenesis | Q34627064 | ||
TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility | Q34713446 | ||
A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells | Q34787867 | ||
Canonical and non-canonical JAK-STAT signaling | Q34855617 | ||
The Wnt signalling pathway | Q34925309 | ||
Beta-catenin hits chromatin: regulation of Wnt target gene activation | Q34967116 | ||
Hormonal, cellular, and molecular control of prostatic development | Q35088639 | ||
A protein kinase C/protein kinase D pathway protects LNCaP prostate cancer cells from phorbol ester-induced apoptosis by promoting ERK1/2 and NF-{kappa}B activities | Q35144545 | ||
Androgen receptor signaling in prostate cancer development and progression | Q35183663 | ||
Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease | Q35452032 | ||
Environment and cancer in Brazil: an overview from a public health perspective | Q35596052 | ||
Beta-catenin signaling in prostate cancer: an early perspective | Q35624511 | ||
Effect of transforming growth factor beta (TGF-β) receptor I kinase inhibitor on prostate cancer bone growth | Q35754279 | ||
Castration-resistant prostate cancer: systemic therapy in 2012 | Q35865011 | ||
IκB kinases modulate the activity of the androgen receptor in prostate carcinoma cell lines. | Q35882191 | ||
MAP kinases and cell migration | Q35889220 | ||
Akt-mediated phosphorylation of Bmi1 modulates its oncogenic potential, E3 ligase activity, and DNA damage repair activity in mouse prostate cancer. | Q35913650 | ||
Mechanism of β-catenin-mediated transcriptional regulation of epidermal growth factor receptor expression in glycogen synthase kinase 3 β-inactivated prostate cancer cells | Q36002945 | ||
Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal | Q36003940 | ||
Role of MMP-2 in the regulation of IL-6/Stat3 survival signaling via interaction with α5β1 integrin in glioma | Q36010641 | ||
Interleukin-6: from basic science to medicine--40 years in immunology | Q36072403 | ||
Changing demography of prostate cancer in Asia | Q36088800 | ||
Wnt signalling and prostate cancer | Q36089054 | ||
Doxycycline regulated induction of AKT in murine prostate drives proliferation independently of p27 cyclin dependent kinase inhibitor downregulation | Q36109815 | ||
Wnt signaling and injury repair | Q36119516 | ||
Sabutoclax, a Mcl-1 antagonist, inhibits tumorigenesis in transgenic mouse and human xenograft models of prostate cancer | Q36172754 | ||
Roles and regulation of Wnt signaling and beta-catenin in prostate cancer | Q36197343 | ||
Proteomic profiling of androgen-independent prostate cancer cell lines reveals a role for protein S during the development of high grade and castration-resistant prostate cancer | Q36298306 | ||
Oncogenic PI3K deregulates transcription and translation | Q36337966 | ||
Risk factors for the onset of prostatic cancer: age, location, and behavioral correlates | Q36375316 | ||
Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells | Q36378963 | ||
Role of Wnts in prostate cancer bone metastases | Q36382153 | ||
Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway | Q36391468 | ||
CCAAT/enhancer-binding proteins: structure, function and regulation | Q24534323 | ||
Diet, supplement use, and prostate cancer risk: results from the prostate cancer prevention trial | Q24594183 | ||
Cell signaling by receptor tyrosine kinases | Q24598357 | ||
Wnt modulators in the biotech pipeline | Q24618567 | ||
AKT/PKB signaling: navigating downstream | Q24657857 | ||
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis | Q24681977 | ||
Pten dose dictates cancer progression in the prostate | Q24791909 | ||
Cancer treatment and survivorship statistics, 2012 | Q27020961 | ||
Dietary flavonoid fisetin: a novel dual inhibitor of PI3K/Akt and mTOR for prostate cancer management | Q27026839 | ||
MYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitors | Q27350187 | ||
The phosphoinositide 3-kinase pathway | Q27860738 | ||
Mechanisms of TGF-beta signaling from cell membrane to the nucleus | Q27860785 | ||
Stem cells, cancer, and cancer stem cells | Q27860878 | ||
Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions | Q28118180 | ||
TGFbeta signaling in growth control, cancer, and heritable disorders | Q28142605 | ||
Role of transforming growth factor beta in human disease | Q28143408 | ||
Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy | Q28176737 | ||
The ABC of APC | Q28205388 | ||
Cancer susceptibility and the functions of BRCA1 and BRCA2 | Q28217784 | ||
Defining the role of mTOR in cancer | Q28235431 | ||
Molecular determinants of resistance to antiandrogen therapy | Q28236889 | ||
Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer | Q28267996 | ||
Signal transduction by the c-Jun N-terminal kinase (JNK)--from inflammation to development | Q28268881 | ||
beta-catenin destruction complex: insights and questions from a structural perspective | Q28276987 | ||
Integrating cell-signalling pathways with NF-kappaB and IKK function | Q28280069 | ||
Role of the STAT1-SH2 domain and STAT2 in the activation and nuclear translocation of STAT1 | Q28287881 | ||
TGFbeta in Cancer | Q28288866 | ||
The c-Fos protein interacts with c-Jun/AP-1 to stimulate transcription of AP-1 responsive genes | Q28291126 | ||
The bottleneck of JNK signaling: molecular and functional characteristics of MKK4 and MKK7 | Q28305659 | ||
Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway | Q28382812 | ||
Nuclear factor-kappaB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression | Q28389404 | ||
Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer. | Q50784946 | ||
Diet and mortality from common cancers in Brazil: an ecological study. | Q51210262 | ||
Fibroblast growth factor receptor signaling through MEK-ERK is required for prostate bud induction. | Q51765900 | ||
Expression of NF-κB-related proteins and their modulation during TNF-α-provoked apoptosis in prostate cancer cells. | Q53251836 | ||
Inhibition of tumor growth and sensitization to chemotherapy by RNA interference targeting interleukin-6 in the androgen-independent human prostate cancer PC3 model. | Q53277140 | ||
MAP2K4/MKK4 expression in pancreatic cancer: genetic validation of immunohistochemistry and relationship to disease course. | Q53362092 | ||
Stat3 activation in prostatic carcinomas. | Q53390466 | ||
Androgen metabolism and JAK/STAT pathway genes and prostate cancer risk. | Q54514315 | ||
The P2Y2/Src/p38/COX-2 pathway is involved in the resistance to ursolic acid-induced apoptosis in colorectal and prostate cancer cells. | Q54516019 | ||
The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. | Q54535188 | ||
Correlation analysis of JAK-STAT pathway components on prognosis of patients with prostate cancer. | Q54580773 | ||
Notch-1 down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells | Q56749698 | ||
THE GENETICS OF BREAST CANCER SUSCEPTIBILITY | Q57272243 | ||
Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease | Q57908314 | ||
Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro | Q71955600 | ||
Detection and analysis of beta-catenin mutations in prostate cancer | Q73260044 | ||
Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse | Q73435294 | ||
The Lynch Syndrome: Melding Natural History and Molecular Genetics to Genetic Counseling and Cancer Control | Q73821909 | ||
Immunoexpression of tumour necrosis factor-alpha and its receptors 1 and 2 correlates with proliferation/apoptosis equilibrium in normal, hyperplasic and carcinomatous human prostate | Q73904625 | ||
Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy | Q73959218 | ||
Characterization of the role of IL-6 in the progression of prostate cancer | Q74587530 | ||
Transforming growth factor beta1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer | Q77164555 | ||
Signaling by the cytokine receptor superfamily | Q77934807 | ||
The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1 | Q79314186 | ||
Ras-MEK-ERK signaling cascade regulates androgen receptor element-inducible gene transcription and DNA synthesis in prostate cancer cells | Q80114515 | ||
Pro-inflammatory cytokines and prostate-specific antigen in hyperplasia and human prostate cancer | Q81050246 | ||
Classical and alternative nuclear factor-κB pathways: a comparison among normal prostate, benign prostate hyperplasia and prostate cancer | Q83887156 | ||
The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study | Q34025763 | ||
Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation | Q34109986 | ||
Cytokine signaling in 2002: new surprises in the Jak/Stat pathway | Q34126053 | ||
IL-6 in autoimmune disease and chronic inflammatory proliferative disease | Q34148654 | ||
The relationship between the roles of BRCA genes in DNA repair and cancer predisposition | Q34163219 | ||
Posttranscriptional and posttranslational regulation of C/EBP delta in G0 growth-arrested mammary epithelial cells | Q34173442 | ||
NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer | Q34277988 | ||
Potentiation of inflammatory CXCL8 signalling sustains cell survival in PTEN-deficient prostate carcinoma. | Q34289623 | ||
Androgen deprivation induces senescence characteristics in prostate cancer cells in vitro and in vivo | Q34295241 | ||
The JAK/STAT signaling pathway | Q34305849 | ||
New complexities for BRCA1 and BRCA2. | Q34348715 | ||
Dietary soy and tea mitigate chronic inflammation and prostate cancer via NFκB pathway in the Noble rat model | Q34372606 | ||
Lysophosphatidic acid enhances vascular endothelial growth factor-C expression in human prostate cancer PC-3 cells. | Q34387665 | ||
PKB/AKT: functional insights from genetic models | Q34389540 | ||
Biological and clinical significance of the JAK-STAT pathway; lessons from knockout mice. | Q34403348 | ||
New strategies for immunosuppression: interfering with cytokines by targeting the Jak/Stat pathway. | Q34412332 | ||
Androgen receptor signaling in androgen-refractory prostate cancer | Q34444942 | ||
Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study | Q34473008 | ||
NFkappaB pathway: a good signaling paradigm and therapeutic target | Q36502786 | ||
Does sunlight prevent cancer? A systematic review | Q36563815 | ||
STAT3 as a central mediator of neoplastic cellular transformation | Q36665485 | ||
Transgenic Wnt/TCF pathway reporters: all you need is Lef? | Q36672673 | ||
Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence | Q36696600 | ||
The many ways of Wnt in cancer | Q36701583 | ||
Concise review: regulation of embryonic stem cell lineage commitment by mitogen-activated protein kinases | Q36705821 | ||
Inhibition of Akt pathways in the treatment of prostate cancer | Q36807494 | ||
Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model | Q36841356 | ||
The role of the BRCA2 gene in susceptibility to prostate cancer revisited | Q36924831 | ||
Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism | Q37001348 | ||
The diverse and contrasting effects of using human prostate cancer cell lines to study androgen receptor roles in prostate cancer | Q37074725 | ||
Small ubiquitin-like modifier protein-specific protease 1 and prostate cancer | Q37074734 | ||
Suppression of Wnt/beta-catenin signaling inhibits prostate cancer cell proliferation | Q37086749 | ||
The MAPK pathway in melanoma | Q37094897 | ||
Biology and significance of the JAK/STAT signalling pathways | Q37146441 | ||
Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality | Q37155349 | ||
Prostate development: a historical perspective | Q37156817 | ||
Intracellular mechanisms of metabolism regulation: the role of signaling via the mammalian target of rapamycin pathway and other routes. | Q37178247 | ||
Molecular alterations in prostate cancer | Q37191507 | ||
Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers | Q37220614 | ||
Does prostate cancer co-opt the developmental program? | Q37254510 | ||
Deciphering the function of canonical Wnt signals in development and disease: conditional loss- and gain-of-function mutations of beta-catenin in mice | Q37259094 | ||
NF-kappaB regulates androgen receptor expression and prostate cancer growth | Q37278416 | ||
Oncogenic activation of androgen receptor | Q37359265 | ||
PIKKing on PKB: regulation of PKB activity by phosphorylation | Q37419888 | ||
FGFR2 abnormalities underlie a spectrum of bone, skin, and cancer pathologies | Q37456169 | ||
Signal integration by JNK and p38 MAPK pathways in cancer development | Q37560607 | ||
Gambogic acid inhibits TNF-α-induced invasion of human prostate cancer PC3 cells in vitro through PI3K/Akt and NF-κB signaling pathways | Q37729931 | ||
Wnt signaling in stem and cancer stem cells | Q37788360 | ||
NFκB/p53 crosstalk-a promising new therapeutic target. | Q37800637 | ||
Tyrosine-kinase inhibitors in the treatment of muscle invasive bladder cancer and hormone refractory prostate cancer | Q37811705 | ||
Steps in prostate cancer progression that lead to bone metastasis | Q37848782 | ||
Increased androgen receptor transcription: a cause of castration-resistant prostate cancer and a possible therapeutic target. | Q37866912 | ||
Oxidative stress and androgen receptor signaling in the development and progression of castration-resistant prostate cancer | Q37912413 | ||
A novel inhibitor of hypoxia-inducible factor-1α P3155 also modulates PI3K pathway and inhibits growth of prostate cancer cells | Q28394160 | ||
Inactivation of Apc in the mouse prostate causes prostate carcinoma | Q28508948 | ||
Pten is essential for embryonic development and tumour suppression | Q28509238 | ||
Fibroblast growth factor receptor 2 tyrosine kinase is required for prostatic morphogenesis and the acquisition of strict androgen dependency for adult tissue homeostasis | Q28512592 | ||
FGF-10 plays an essential role in the growth of the fetal prostate | Q28513689 | ||
Role of epithelial cell fibroblast growth factor receptor substrate 2alpha in prostate development, regeneration and tumorigenesis | Q28588423 | ||
Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation | Q28638584 | ||
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism | Q29547302 | ||
STATs and gene regulation | Q29547796 | ||
The phosphatidylinositol 3-Kinase AKT pathway in human cancer | Q29547860 | ||
The STATs of cancer--new molecular targets come of age | Q29614601 | ||
Wnt proteins are lipid-modified and can act as stem cell growth factors | Q29615009 | ||
TGF-beta signaling in tumor suppression and cancer progression | Q29615427 | ||
The functions and regulation of the PTEN tumour suppressor | Q29615536 | ||
MAP kinase signalling pathways in cancer | Q29615542 | ||
Proximal events in Wnt signal transduction | Q29616162 | ||
Crosstalk in NF-κB signaling pathways | Q29617418 | ||
Synergistic activation of stress-activated protein kinase 1/c-Jun N-terminal kinase (SAPK1/JNK) isoforms by mitogen-activated protein kinase kinase 4 (MKK4) and MKK7 | Q29999265 | ||
Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites | Q30309352 | ||
M-HIFU inhibits tumor growth, suppresses STAT3 activity and enhances tumor specific immunity in a transplant tumor model of prostate cancer | Q30465410 | ||
Activation of mitogen-activated protein kinase associated with prostate cancer progression. | Q30473093 | ||
K-ras and Wnt signaling synergize to accelerate prostate tumorigenesis in the mouse | Q30856712 | ||
TGF-beta signaling: positive and negative effects on tumorigenesis | Q31034737 | ||
Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex | Q31038919 | ||
Constitutive activation of JAK-STAT3 signaling by BRCA1 in human prostate cancer cells | Q31864260 | ||
Prostate cancer cell adhesion to bone marrow endothelium: the role of prostate-specific antigen | Q33199699 | ||
JAK/STAT-dependent gene regulation by cytokines. | Q33220017 | ||
BRAF activation initiates but does not maintain invasive prostate adenocarcinoma | Q33392719 | ||
Effective prostate cancer chemopreventive intervention with green tea polyphenols in the TRAMP model depends on the stage of the disease | Q33416685 | ||
Gene expression relationship between prostate cancer cells of Gleason 3, 4 and normal epithelial cells as revealed by cell type-specific transcriptomes | Q33519740 | ||
Role of IAPs in prostate cancer progression: immunohistochemical study in normal and pathological (benign hyperplastic, prostatic intraepithelial neoplasia and cancer) human prostate | Q33524557 | ||
Activation of the Akt survival pathway contributes to TRAIL resistance in cancer cells | Q33564264 | ||
Transcription factor Stat3 stimulates metastatic behavior of human prostate cancer cells in vivo, whereas Stat5b has a preferential role in the promotion of prostate cancer cell viability and tumor growth. | Q33745272 | ||
Androgen-induced cell migration: role of androgen receptor/filamin A association | Q33831959 | ||
A constitutively activated form of the p110beta isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice | Q33934457 | ||
Interleukin-6 and prostate cancer progression | Q33943225 | ||
Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma | Q33992803 | ||
CTNNB1 mutation analysis is a useful tool for the diagnosis of desmoid tumors: a study of 260 desmoid tumors and 191 potential morphologic mimics | Q84529552 | ||
Breast cancer in a BRCA2 mutation carrier with a history of prostate cancer | Q84592928 | ||
Non-canonical NF-κB signaling activation and regulation: principles and perspectives | Q37948121 | ||
NF-κB signaling in prostate cancer: a promising therapeutic target? | Q37956492 | ||
A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes | Q37968375 | ||
Androgen receptor (AR) aberrations in castration-resistant prostate cancer. | Q37975896 | ||
The Jak/STAT pathway | Q37989935 | ||
Environmental exposures and prostate cancer | Q37990121 | ||
Androgen action and metabolism in prostate cancer | Q37997571 | ||
Perspectives on mTOR inhibitors for castration-refractory prostate cancer. | Q38029399 | ||
Antitumor activity of NF-kB decoy oligodeoxynucleotides in a prostate cancer cell line. | Q38327864 | ||
Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone | Q38339139 | ||
IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. | Q38343244 | ||
International variation in prostate cancer incidence and mortality rates. | Q38935652 | ||
Autophagy modulators sensitize prostate epithelial cancer cell lines to TNF-alpha-dependent apoptosis | Q39290799 | ||
SPRY2 loss enhances ErbB trafficking and PI3K/AKT signalling to drive human and mouse prostate carcinogenesis | Q39339428 | ||
Oxidative stress and prostate cancer progression are elicited by membrane-type 1 matrix metalloproteinase | Q39362236 | ||
The AKT/NF-κB inhibitor xanthohumol is a potent anti-lymphocytic leukemia drug overcoming chemoresistance and cell infiltration. | Q39374501 | ||
Role and regulation of STAT3 phosphorylation at Ser727 in melanocytes and melanoma cells | Q39379627 | ||
Hypoxia-induced up-regulation of aquaporin-1 protein in prostate cancer cells in a p38-dependent manner | Q39380390 | ||
High levels of p110δ PI3K expression in solid tumor cells suppress PTEN activity, generating cellular sensitivity to p110δ inhibitors through PTEN activation | Q39385359 | ||
Increased TGF-β1-mediated suppression of growth and motility in castrate-resistant prostate cancer cells is consistent with Smad2/3 signaling | Q39415532 | ||
Mitogen-activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer | Q39446502 | ||
GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway | Q39458307 | ||
β-Caryophyllene oxide inhibits growth and induces apoptosis through the suppression of PI3K/AKT/mTOR/S6K1 pathways and ROS-mediated MAPKs activation | Q39472593 | ||
Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer | Q39475898 | ||
Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma | Q39487932 | ||
CCI-779 inhibits cell-cycle G2-M progression and invasion of castration-resistant prostate cancer via attenuation of UBE2C transcription and mRNA stability | Q39540207 | ||
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer | Q39541646 | ||
Expression of nodal and nodal receptors in prostate stem cells and prostate cancer cells: autocrine effects on cell proliferation and migration | Q39545341 | ||
Expression profile of WNT molecules in prostate cancer and its regulation by aminobisphosphonates. | Q39587433 | ||
Induction of apoptosis and inhibition of PI3K/Akt pathway in PC-3 and LNCaP prostate cancer cells by ethanolic neem leaf extract | Q39601021 | ||
Characterization of soy-based changes in Wnt-frizzled signaling in prostate cancer. | Q39643199 | ||
P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
P6216 | copyright status | copyrighted | Q50423863 |
P921 | main subject | prostate cancer | Q181257 |
P304 | page(s) | 920612 | |
P577 | publication date | 2013-04-29 | |
P1433 | published in | Prostate Cancer | Q26842072 |
P1476 | title | Dissecting Major Signaling Pathways throughout the Development of Prostate Cancer | |
P478 | volume | 2013 |
Q42115437 | A novel microRNA-1207-3p/FNDC1/FN1/AR regulatory pathway in prostate cancer |
Q28817152 | Combined genetic and epigenetic interferences with interferon signaling expose prostate cancer cells to viral infection |
Q38160495 | Disruption of prostate epithelial differentiation pathways and prostate cancer development |
Q60955174 | Drosophila Jak/STAT Signaling: Regulation and Relevance in Human Cancer and Metastasis |
Q36331604 | Identification of shared and unique susceptibility pathways among cancers of the lung, breast, and prostate from genome-wide association studies and tissue-specific protein interactions |
Q49210539 | Interleukin-6 and Interferon-α Signaling via JAK1-STAT Differentially Regulate Oncolytic versus Cytoprotective Antiviral States. |
Q37297497 | Lycopene inhibits the cell proliferation and invasion of human head and neck squamous cell carcinoma |
Q38918320 | MAPK and JAK/STAT pathways targeted by miR-23a and miR-23b in prostate cancer: computational and in vitro approaches. |
Q50573927 | Maternal Obesity, Cage Density, and Age Contribute to Prostate Hyperplasia in Mice. |
Q90048237 | Mechanism of Anti-Cancer Activity of Curcumin on Androgen-Dependent and Androgen-Independent Prostate Cancer |
Q38709756 | Mechanotransduction-Induced Reversible Phenotypic Switching in Prostate Cancer Cells |
Q64963067 | MicroRNA-30e inhibits adhesion, migration, invasion and cell cycle progression of prostate cancer cells via inhibition of the activation of the MAPK signaling pathway by downregulating CHRM3. |
Q64062289 | NOD-like receptors: major players (and targets) in the interface between innate immunity and cancer |
Q46537204 | Prostate cancer health disparities: An immuno-biological perspective |
Q37082974 | Reciprocal regulation of long noncoding RNAs THBS4‑003 and THBS4 control migration and invasion in prostate cancer cell lines |
Q35758944 | Relative mRNA expression of prostate-derived E-twenty-six factor and E-twenty-six variant 4 transcription factors, and of uridine phosphorylase-1 and thymidine phosphorylase enzymes, in benign and malignant prostatic tissue |
Q34482912 | Sex hormone-dependent tRNA halves enhance cell proliferation in breast and prostate cancers. |
Q33688960 | The NLR-related protein NWD1 is associated with prostate cancer and modulates androgen receptor signaling. |
Q91943954 | The Prospect of Identifying Resistance Mechanisms for Castrate-Resistant Prostate Cancer Using Circulating Tumor Cells: Is Epithelial-to-Mesenchymal Transition a Key Player? |
Q35229964 | WMAXC: a weighted maximum clique method for identifying condition-specific sub-network |
Search more.